An Antiviral Drug Favipiravir Was Approved For Treating Against COVID 19 .pdf
Original filename: An Antiviral Drug Favipiravir Was Approved For Treating Against COVID-19.pdf
This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 08/07/2020 at 09:07, from IP address 103.121.x.x.
The current document download page has been viewed 25 times.
File size: 157 KB (3 pages).
Privacy: public file
Download original PDF file
An Antiviral Drug Favipiravir Was
Approved For Treating Against
Favipiravir is a new type of RNA polymerase inhibitor, acting on viral genetic
copying to prevent its reproduction. It is sold under the brand names Avigan,
Abigan and FabiFlu, which is an antiviral medication used to treat influenza. In
February 2020, favipiravir has being studied in China for experimental
treatment of the emergent COVID-19. Trials are also being planned in Japan.
On 20th, Jun., Glenmark Pharmaceuticals, which is the fifth-biggest
pharmaceutical company in India announced the launch of antiviral drug
Favipiravir (brand name FabiFlu®) for the treatment of mild to
moderate Covid-19 patients.
Glenmark's Fabiflu is the first oral Favipiravir-approved medication for the
treatment of COVID-19 and has been launched in few centers. The Drug
Controller General of India approved the anti-viral for 'restricted emergency
use' for treatment of mild to moderate cases, which accounts for a majority of
Monika Tandon, vice president and head, clinical development at Glenmark said,
there are 150 COVID-19 patients enrolled in the trial, 90 were mild and 60 were
moderate patients. Their conditions had not deteriorated to severe or critical
stages of the disease.
It is key to start the drug early, Tandon added, “ High rate of viral replication
can be controlled with early use of antiviral drugs and it is seen to limit immune
response mediated damage as immune response subsides quickly.”
The details of the trial results are yet to be published, but the company said
most patients gradually recovered in a week. Others took almost two weeks to
Nearly 18 global clinical trials in over 3,000 patient subjects have been
conducted globally. Tandon said while Glenmark’s trial was on 150 patients, the
data was corroborated with other trials in USA, Canada, Italy, China, France and
Favipiravir is also approved for treating COVID-19 in Japan and nearly 2,050
patients have already been administered Favipiravir. "Japan’s clinical use
showed high recovery rates at both 7 days (74%) and 14 days (88%) of therapy
in both mild and moderate patients."
Another study in 390 patients in Russia showed 68% of those on Favipiravir
reached fever resolution on day 3 versus day 6 for those on standard therapy.
Favipiravir is also approved by Italy and China for experimental
use/compassionate use in COVID-19 and few countries in the Middle East.
Reports say Hyderabad-based drug maker Optimus Pharma has started
shipping the antiviral tablet Favipiravir to the UAE, where the drug is approved.
Favipiravir and Remdesivir are two drugs that have been proved to be very
effective in the treatment of COVID-19. Hunan Huateng Pharmaceutical Co.,
Ltd. is a leading pharmaceutical company focusing on R&D of pharmaceutical
intermediates. We have extensive experience in the development
of new antiviral drugs intermediates such as Favipiravir/Avigan
intermediates, Remdesivir intermediates, Baloxavir Marboxil intermediates and
so on. We can provide Favipiravir intermediates CAS No. 259793-96-9, CAS No.
55321-99-8, CAS No. 259793-88-9, CAS No. 356783-16-9, CAS No.
356783-28-3, CAS No. 356783-31-8 and so on.
: Glenmark announces launch of Favipiravir to treat Covid patients
: A preliminary report of the Favipiravir Observational Study